Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amanta HealthcareNSE:AMANTA +1.99%14 Return-on-Tangible-Equity is 10.08% as of Mar. 2026, which is 7% above its 10-year median of 9.44. GuruFocus rates NSE:AMANTA with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 901 Drug Manufacturers companies, Amanta Healthcare ranks worse than 54.05% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Amanta Healthcare's annualized net income for the quarter that ended in Mar. 2026 was ₹221 Mil. Amanta Healthcare's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹2,195 Mil. Therefore, Amanta Healthcare's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 10.08%.
The historical rank and industry rank for Amanta Healthcare's Return-on-Tangible-Equity or its related term are showing as below:
NSE:AMANTA'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -3.31 Med: 9.44 Max: 83.13
Current: 6.5
During the past 5 years, Amanta Healthcare's highest Return-on-Tangible-Equity was 83.13%. The lowest was -3.31%. And the median was 9.44%.
NSE:AMANTA's Return-on-Tangible-Equity is ranked worse than 54.05% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.87
vs NSE:AMANTA: 6.50
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Amanta Healthcare Return-on-Tangible-Equity Related Terms
Amanta Healthcare Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Amanta Healthcare's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:AMANTA vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amanta Healthcare's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amanta Healthcare Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amanta Healthcare's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Amanta Healthcare's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 10.08% mean?
Amanta Healthcare (NSE:AMANTA) has a Return-on-Tangible-Equity of 10.08% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Amanta Healthcare and its competitors. This is near median its historical median of 9.44. According to the industry distribution chart, Amanta Healthcare ranks #487 out of 901 companies in the Drug Manufacturers industry, placing it in the top 54.1%.
Is Amanta Healthcare's Return-on-Tangible-Equity too high?
Amanta Healthcare's current Return-on-Tangible-Equity of 10.08% is near median its 10-year median of 9.44. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.87. Amanta Healthcare's value of 10.08% is 28.1% above this industry median. Based on the distribution chart, Amanta Healthcare ranks #487 out of 901 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Amanta Healthcare has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Amanta Healthcare's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Amanta Healthcare ranks #487 out of 901 companies for Return-on-Tangible-Equity. This places Amanta Healthcare in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.87. Amanta Healthcare's value of 10.08% is 28.1% above this benchmark. While the company's 10-year median is 9.44 vs. the industry median of 7.87, Amanta Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.87, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amanta Healthcare's current Return-on-Tangible-Equity of 10.08% is 28.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Amanta Healthcare and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amanta Healthcare's current Return-on-Tangible-Equity is 10.08%, which is near median its own 10-year median of 9.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amanta Healthcare stock overvalued right now?
Amanta Healthcare (NSE:AMANTA) has a current Return-on-Tangible-Equity of 10.08%. The current Return-on-Tangible-Equity is 10.08%, which is near median its 10-year median of 9.44 and 28.1% above the Drug Manufacturers industry median of 7.87. Amanta Healthcare's overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Amanta Healthcare (NSE:AMANTA), the current Return-on-Tangible-Equity is 10.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amanta Healthcare Ltd is a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products - parenteral products, being packed in plastic container with Aseptic Blow-Fill-Seal and Injection Strech Blow Moulding technology. It manufactures large volume parenterals and small volume parenterals in six therapeutic segments. It also manufactures medical devices. The company manufactures fluid therapy, formulations, diluents, ophthalmic, respiratory care and irrigation solutions in therapeutic segment and products like irrigation, first-aid solution, eye lubricants etc. in medical device segment. It offers wide range of closure systems, such as nipple head, twist-off, leur-lock and screw types and container fill-volume till 1000 ml.
14GF Score
Get the complete analysis for NSE:AMANTA
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AMANTA has been successfully added to your 
